Global Opioid Induced Constipation Drugs Market Size, Share, Growth, Global Trends, Industry Analysis and Forecast to 2027Price: 3200/- USD | Published Date: September 6, 2020 |
The global Opioid Induced Constipation (OIC) drugs Market has been projected to grow at the CAGR of 4.6% market during 2020-2027 and expected to reach up to $ 3,049.9 million in terms of revenue by 2025. The OIC drugs market is expected to show significant growth during the forecast period on account of increasing demand for opioid drugs globally, promising pipeline molecules and regulatory approvals to the newer medication would influence the market growth of OIC drugs worldwide.
The global opioid induced constipation (OIC) drugs market is anticipated to grow significantly during the forecast period due to rising opioid prescriptions for non-cancer pain in the previous decade. It is observed that Methylnaltrexone bromide, lubiprostone, and naloxegol drugs are widely accepted in the market for the treatment of OIC. Among these, methylnaltrexone bromide currently held the largest market share and is expected to show significant growth during the forecast period because it provides good relief from constipation in terminally ill patients who do not respond to laxatives. Currently, Naloxegol is a widely accepted OIC drugs for the treatment of constipation and is expected to grow at the highest CAGR during the forecast period due it relieves constipation without reducing the pain-relieving effects of opioids is the major factor would fuel the growth of the Naloxegol market during the forecast period. Promising pipeline molecules such as Naldemedine, Elobixibat, and Dolcanatide expected to drive the growth of OIC drugs market during the forecast period. Currently, North America and Europe are expected to be the largest regional market for OIC drugs worldwide due to higher cost of treatment, upsurge in funding by government and adoption of novel medication are influencing the growth of the OIC drugs market in North America and Europe.
Market Segment Insights:
For the purpose of the study global OIC drugs market is studied for drug type and prescription type. Pipeline drug analysis (Naldemedine, Elobixibat, and Dolcanatide), Methylnaltrexone Bromide, Lubiprostone, and Naloxegol are primarily considered in the drug segment. On the other hand, on the basis of the type of prescription market is segmented as prescribed drugs and over the counter drugs.
Global OIC Drugs Market Segmentation:
By Drug Type, 2018–2027 ($ Million)
- Methylnaltrexone Bromide
- Pipeline Drug Analysis: Naldemedine, Elobixibat and Dolcanatide
By Prescription Type, 2018–2027 ($ Million)
- Prescribed Drugs
- Over the Counter Drugs
By Geography, 2018-2027 ($ Million)
- North America
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
For the purpose of this study, the global OIC drugs market is regionally categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa markets. These regional markets are further sub-segmented into top country-level markets that majorly determine the regional industry trends. Among the considered regional markets, North America and Europe currently dominate the global OIC drugs market, with the United States being the largest county-level market in North America due to the higher cost of medication, higher consumption of opioids for pain-relieving and upsurge funding by government agencies are driving the OIC drugs market. On the other hand, Asia Pacific is anticipated to be the fastest-growing market for OIC drugs due to increasing healthcare awareness, improvement in economic conditions, rapid adoption of pain-relieving opioids for non-cancer ailments and limited treatment availability would drive the market growth in Asia pacific.
Market Competition Assessment:
The major players currently operating in the global OIC drugs market include Astrazenenca, Cubist Pharmaceuticals (Adolor Corporation), Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals, Inc., Pfizer Inc., Progenics Pharmaceuticals Inc., Salix Pharmaceuticals Ltd., Shionogo & Co Ltd, Sucampo Pharmaceuticals and Synergy Pharmaceuticals Inc.
List of Key Companies:
- Cubist Pharmaceuticals (Adolor Corporation)
- Daiichi Sankyo Co. Ltd.
- Ironwood Pharmaceuticals, Inc.
- Progenics Pharmaceuticals Inc
- Salix Pharmaceuticals Ltd
- Shionogo & Co Ltd
- Sucampo Pharmaceuticals
- Synergy Pharmaceuticals Inc.
Request a free report sample @ https://www.researchcorridor.com/request-sample/?id=91456
Table of Content:
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
Chapter 2 Executive Summary
2.1 Global OIC Drugs Market Portraiture
2.2 Global OIC Drugs Market, by Drug Type, 2019 ($ Million)
2.3 Global OIC Drugs Market, by Prescription Type, 2019 ($ Million)
2.4 Global OIC Drugs Market, by Geography, 2019 (Value %)
Chapter 3 Global OIC Drugs Market Analysis
3.1 Global OIC Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.3 Attractive Investment Proposition, 2019
3.4 Competitive Landscape Assessment, by Key Market Players
Chapter 4 Global OIC Drugs Market Analysis, by Drug Type, 2018-2027 ($ Million)
4.2 Methylnaltrexone Bromide
4.7 Pipeline Drug Analysis: Naldemedine, Elobixibat and Dolcanatide
Chapter 5 Global OIC Drugs Market Analysis, by Prescription Type 2018-2027 ($ Million)
5.2 Prescribed Drugs
5.3 Over the Counter Drugs
Chapter 6 Global OIC Drugs Market, by Geography, 2018-2027 ($ Million)
6.2 North America (U.S. & Canada)
6.3 Europe (U.K., Germany & Rest of Europe)
6.4 Asia Pacific (China, Japan, and Rest of APAC)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)
Chapter 7 Company Profiles
7.2 Cubist Pharmaceuticals (Adolor Corporation)
7.3 Daiichi Sankyo Co. Ltd.
7.4 Ironwood Pharmaceuticals, Inc.
7.5 Pfizer Inc.
7.6 Progenics Pharmaceuticals Inc
7.7 Salix Pharmaceuticals Ltd.
7.8 Shionogo & Co Ltd
7.9 Sucampo Pharmaceuticals
7.10 Synergy Pharmaceuticals Inc.
$4800/- Multi User License $6400/- Corporate License
- Markets in over 150 countries analyzed granularly
- 35% of our total client are returning clients
- 100,000+ data points in our comprehensive database
- 24x5 availability - we are always there when you need us
- Our expert team will assist you with all research need and customization
- Our expert research analysts will resolve your every query before and after purchasing the report
- We focus on the accuracy and quality of the report
- Our analyst will provide deep insights into the report
Call Us: +1 520-686-7060